Skip to main content
OpenTrials
Completed

NCT Number: NCT02324725

Biomarkers of Injectable Extended Release Naltrexone Treatment

This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Center for the Studies of Addiction

Philadelphia, Pennsylvania, 19104, United States

About this study

This study is using blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) to examine the brain predictors of adherence and outcomes of opioid antagonist therapy. Opioid-dependent intravenous heroin users are offered up to 3 monthly injections of the extended-release naltrexone (XRNTX) contingent upon successful outpatient non-opioid detoxification, with an additional 4 weeks of follow up. Brain responses to heroin-related pictures are recorded using fMRI prior to the 1st XRNTX injection and approximately 2 weeks thereafter the 1st XRNTX injection. Primary clinical variables include the number of injections (maximum of 3) accepted by participants, change in self-reported craving for opioids after exposure to drug-related visual cues during the brain fMRI sessions, urine levels of ten commonly abused substances and self-report of cigarette use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DSM-IV-TR diagnosis of opioid dependence, active opioid use, confirmed by urine toxicology screen and self-reported monthly intravenous heroin use for more than 2 weeks in the past 3 months
  • urine toxicology screen negative for opioids after detoxification
  • good physical health as indicated by history and physical examination, screening blood work-up and urinalysis.

Exclusion criteria

  • chronic medical illnesses;
  • current use of medications potentially confounding brain activity, such as anti-dopaminergic agents, anti-depressants and beta-blockers;
  • current DSM-IV-TR Axis I psychiatric disorders other than opioid and nicotine dependence;
  • life time history of concurrent IV cocaine and heroin (speedball) administration;
  • pregnancy or breastfeeding;
  • history of clinically significant head trauma;
  • contraindications for naltrexone treatment including medical conditions requiring opioid analgesics, e.g. chronic pain or planned surgery, obesity, elevated liver enzymes (> 3 times upper limit of normal), failure to complete opioid detoxification
  • contraindications for MRI, i.e. indwelling magnetically active foreign bodies and phobia to enclosed spaces

Treatment and study plan

Naltrexone

Drug

Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly

Other names: Vivitrol ®

Primary outcomes

  1. Brain response to heroin-related visual cues

    Time frame: 1 hour

    Brain, behavioral and motivational (e.g. craving) response to audiovisual drug-related and control stimuli (images, smells and sounds) and to standard tasks of decision making, self-appraisal, response inhibition, social interaction and reward processing.

Secondary outcomes

  1. Cigarettes smoked per day

    Time frame: 6 months

    behavioral

  2. Urine toxicology

    Time frame: 6 months

    Urine toxicology for methamphetamine, amphetamines, cannabis, cocaine, oxycodone, buprenophine, methadone, opioids, benzodiazepines and barbiturates.

  3. Injections

    Time frame: 3 months

    Number of injections (maximum of 3) accepted by participants

  4. Motivational response to opioid-related visual cues measured by self-reported craving for opioids

    Time frame: 2 hours

    Change in self-reported craving for opioids after exposure to opioid-related visual cues during functional MRI sessions

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Biomarkers of Disease and Response to Treatment in Opioid Addiction

Important dates

Study start
2011
Primary completion
2021
Study completion
2021
First posted
Dec 24, 2014
Registry last updated
Jan 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.